Sachs Associates’ Post

🔬 The life sciences M&A landscape is being shaped by oncology and rare diseases. Leading pharmaceutical giants like Pfizer, Novartis, and Roche, alongside biotech innovators such as Celgene, Biogen, and Gilead Sciences, are making strategic acquisitions to expand their portfolios. This trend, driven by a deepening understanding of these disease areas and potential for significant ROI, also sees growing partnerships between big pharma, biotech startups, and academic institutions, accelerating the development of breakthrough therapies. #LifeSciences #Oncology #RareDiseases #MandA #HealthcareInnovation Read more in one of our latest article “Exploring the Dominance of Oncology and Rare Diseases in Life Science M&A” 📖 https://ow.ly/B4yr50SNrbk

Theranostics Market worth $4.3 billion by 2028 Download PDF Brochure:-https://lnkd.in/d3tt2aX9 The global theranostics market in terms of revenue was estimated to be worth $2.1 Billion in 2023 and is poised to reach $4.3 Billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US). 𝐎𝐭𝐡𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Siemens Healthineers Novartis Pfizer AstraZeneca Johnson & Johnson Sanofi GSK Eli Lilly and Company Bristol Myers Squibb AbbVie. Roche Diagnostics UK & Ireland GE HealthCare Philips Abbott Boston Scientific Medtronic Cardinal Health Thermo Fisher Scientific QIAGEN Illumina, PerkinElmer, Hologic, Inc. Agilent Technologies, Canon Medical Systems Europe Beckman Coulter Diagnostics Bio-Rad Laboratories, Invicro Nordic Nanovector ASA ImaginAb, Endocyte, Celgene Nektar Therapeutics Bayer | Pharmaceuticals Molecular Partners Isarna Therapeutics GmbH Cancer Research UK (CRUK) Zymeworks Inc. Arcus Biosciences Exelixis, MacroGenics, Inc. #Theranostics #PrecisionMedicine #PersonalizedHealthcare #OncologyResearch #MolecularDiagnostics

🌟 Merck to acquire eye-focused drug developer EyeBio for up to $3 Billion! 🌟 Exciting news in the biotech world! Merck has announced its agreement to acquire the privately held EyeBio, a leader in retinal disease therapies, for as much as $3 billion. This acquisition is part of Merck’s strategic efforts to bolster its future growth and expand its portfolio. 💼💊 📅 Deal Details: Total Value: Up to $3 billion Cash Payment: $1.3 billion Milestone Payments: $1.7 billion Closing: Expected in Q3 2024 What Does This Mean? Merck will gain access to EyeBio's promising retinal disease drug, Restoret, currently in early-stage trials for diseases characterized by blood vessel abnormalities leading to impaired vision. Additionally, Restoret is set to enter mid-stage trials for diabetic macular edema in the second half of 2024. 🧬 👁️ Why This Acquisition? As Merck’s blockbuster cancer immunotherapy Keytruda is set to lose exclusivity by the end of the decade, the company has been actively seeking acquisitions up to $15 billion to sustain its growth trajectory. This year alone, Merck has secured two major deals, with EyeBio being the latest addition. 🚀 About EyeBio: Founded by: SV Health Investors Leadership: Backed by Kathy Bingham, former head of the UK’s Covid-19 vaccine taskforce Operations: Based in London with operations in the US and UK Strategic Impact: This acquisition not only strengthens Merck’s pipeline in ophthalmology but also aligns with its long-term strategy to diversify and enhance its drug portfolio, ensuring continued innovation and market leadership. 🌍🔬 #Merck #EyeBio #Biotech #Pharma #HealthcareInnovation #Ophthalmology #RetinalDiseases #MergersAndAcquisitions #DrugDevelopment #MedicalResearch

With looming patent cliffs, Big Pharma are hungry to fill their pipelines via M&A and licensing deals. Here are the top deals in January 2024:   💸 Novartis have been busy with their $250M upfront acquisition of Calypso Biotech, a $185M+ RNAi licensing deal with Argo Biopharma and up to $1.2B and $1.3B collaborations with Isomorphic Labs and Voyager Therapeutics, Inc.   💸 Eli Lilly and Company also announced a collaboration with Isomorphic, leveraging the Google/Alphabet launched company's #AlphaFold platform   💸 Johnson & Johnson make their move in the #ADC space, with a $2B acquisition of Ambrx   💸 Merck Group bolstered their #cancer #immunotherapy pipeline with a $680M acquisition of Harpoon Therapeutics   💸 Takeda paid $300M+ to license Protagonist Therapeutics' phase 3 peptide mimetic for rare #hematology disorders   💸 Sanofi acquired Inhibrx, Inc. for $1.7B for the biotech's biologic Alpha-1 Antitrypsin Deficiency (#AATD) asset   💸 GSK acquired Aiolos Bio for $1B + $400M in milestone payments for the 2 month old company's phase 2 asthma biologic

💊29 Biotech/Pharma Owned a Blockbusters in 2023! The leading therapeutic areas included #Oncology, #Cardiometabolic, and #Autoimmune diseases. Major contributors were Roche, Johnson & Johnson, Novartis, AstraZeneca, and AbbVie with global sales of $178 Billion, showcasing a diverse range of treatments from immunology to neurosciences. 💊 🔎A significant percentage of those blockbusters will soon lose their exclusivity (LOE) in the next 6 years, which means that pharmas will have to replace them with significant number of new drugs coming from biotech: This is a great opportunity for Biotech licensing, making it a strategic way for pharmaceutical companies to gain access to new groundbreaking drugs. #pharmablockbusters #LOE #biotech

𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The research report encompasses an overview of the development of the Cancer Janus Kinase Inhibitors industry chain, focusing on its applications in Hospitals (Ruxolitinib, Momelotinib) and Ambulatory Surgical Centers (Ruxolitinib, Momelotinib). It highlights key enterprises in both developed and developing markets while analyzing cutting-edge technology, patents, hot applications, and market trends of Cancer Janus Kinase Inhibitors. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/guSqh8-w *𝗕𝘆 𝗧𝘆𝗽𝗲: Ruxolitinib, Momelotinib, Lestaurtinib, Pacritinib, *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Ambulatory Surgical Centers, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Abbott, Asana BioSciences, LLC, AstraZeneca, Celonic Group, Dynamic Pharma S.A. – Δυναμική Φαρμακαποθήκη Α.Ε., Eli Lilly and Company, Gilead Sciences, Hanmi Pharmaceuticals, Incyte, Kyowa Hakko USA, Moleculin Biotech, Inc., Pfizer, Portola Pharmaceuticals #januskinaseinhibitors #cancerresearch #cancertreatment #oncology #drugdevelopment #cancertherapeutics #pharmaceuticals #biomedicalscience #jakinhibitors #precisionmedicine

Stories making headlines today in the biopharma industry: In a significant blow, Gilead's Trodelvy has underperformed in the Phase III trial for non-small cell lung cancer, leading to an impactful drop of 10% in Gilead’s share price. This has put other similar offerings from AstraZeneca and Daiichi Sankyo under the microscope. On a brighter note, new hibernation research holds the promise of redefining weight-loss medications, potentially benefiting even astronauts. Regrettably, in light of subpar results from Alzheimer's drug trials, Roche and AC Immune have opted to end their partnership. However, cheering news comes from Ionis Pharmaceuticals with a successful Phase III trial for a rare disease drug marking significant progress in their commercialization efforts. Cara Therapeutics, facing financial challenges, has made the tough decision to lay off staff and cease the Phase III kidney disease program to sustain longer. Biotech headlines have also noted encouraging Phase IIb data for Sagimet's NASH treatment, the FDA lifting a hold on Pharvaris IND and Dianthus securing a notable $230M in funding. In an exciting development, two biotechnology companies have amalgamated to form Calluna, backed by €75M in funding for the progress of antibody-based immunotherapies. ArriVent is charting its growth path by planning a $135M IPO, marking the second notable biotech IPO of the year. In a leadership update, Apnimed has brought onboard an experienced Pfizer and Biohaven executive as the company's inaugural Chief Commercial Officer. On the transaction front, Coherus BioSciences has divested its Lucentis biosimilar to Sandoz for $170M, redirecting its focus to oncology assets. In a less fortunate turn of events, patient-pharmaceutical connection platform LunaDNA has indicated its intent to cease operations. #pharma #biotech #topstories #biodatastudio

The Life Science sector continues to thrive with groundbreaking developments and major investments. Here are some of the most notable highlights from this week: Rezolute, Inc. has received FDA clearance of its IND application for a Phase 3 registrational study of RZ358, targeting the treatment of hypoglycemia due to tumor hyperinsulinism. Exelixis announced that the U.S. FDA has accepted its supplemental new drug application for Cabozantinib, aimed at patients with advanced neuroendocrine tumors. Shinobi Therapeutics secured a $59 million grant from the Japanese Agency for Medical Research and Development. Sangamo Therapeutics, Inc. signed a licensing agreement with Genentech, which could be worth up to $1.9 billion. Karius obtained a BARDA contract to expand the agnostic detection of pathogens. Plonts launched its plant-based cheese with a $12 million seed round in New York City and San Francisco. Invenio Imaging enrolled the first patients in a U.S. pivotal study of its AI-based image analysis module for lung cancer. Stay tuned for more updates as we continue to follow the latest trends and breakthroughs in the life sciences industry! #LifeScience #Biotech #HealthTech #Innovation #AI #Healthcare #ClinicalTrials #FDAApproval #Pharma #LifeScience #HealthcareInnovation #AIinHealthcare #Biopharma #DrugDevelopment #Pharmaceuticals #BiotechNews #MedTech #ResearchAndDevelopment #FDA

With #AACR24 almost upon us and set to be a great in-person event once again, we thought of making everyone's life a bit easier in terms of planning attendance, by sharing an AACR planner in Excel format. Scan the QR code below or use this link https://bit.ly/3vBd8of to access the document. No sign-in required but feel free to share this post if you find it useful! See you in San Diego! #oncology #haematology #hematology #strategy #LucidQuest #competitiveintelligence Takeda Oncology Novartis The Janssen Pharmaceutical Companies of Johnson & Johnson Bayer Daiichi Sankyo US AstraZeneca AbbVie Amgen BeiGene Blueprint Medicines Boehringer Ingelheim Bristol Myers Squibb Coherus BioSciences Eisai US EMD Serono, Inc. Exelixis FibroGen, Inc. Foundation Medicine Genentech Roche Gilead Sciences Incyte Ipsen Jazz Pharmaceuticals Legend Biotech Medtronic Myriad Genetics Myovant Sciences PathAI Pfizer Regeneron Sanofi Seagen Servier Takeda

Commit Biologics welcomes Mikkel Wandahl Pedersen, as its new Chief Scientific Officer🚀   With over two decades of experience in #antibody-based drug discovery and development, Mikkel further strengthens our leadership team as we continue to advance our Bispecific Complement Engaging (#BiCE™) technology, designed to revolutionise treatments for #cancer and #autoimmune disease. 💊   Mikkel joins us from Nykode Therapeutics where, as CSO, he successfully created and executed a new research strategy, scaled the research organisation to support an expanding pipeline, and spearheaded key collaborations with external pharmaceutical partners.   He brings to Commit a wealth of knowledge in #immunooncology and #autoimmune research   To learn more about Mikkel's background see the press release, linked in the comments below 👇.   #CSO #Leadership #ComplementSystem